Immobilized IL-17A His Tag Protein, Human(S0A4023) can bind Secukinumab. The EC50 for this effect is 43.23 ng/mL.
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | IL-17A |
| Synonyms | Interleukin-17A, Cytotoxic T-lymphocyte-associated antigen 8 (CTLA-8), CTLA8, IL17 |
| Accession | Q16552 |
| Clone Number | S-SC013 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1,k |
| Application | Blocking of IL-17A signaling Functional assays |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ELISA | 1.221-5000 ng/ml |
Background
Secukinumab is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A.
Picture
Picture
ELISA

